Literature DB >> 25168938

Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays.

Joanne van Ryn1, Oliver Grottke2, Henri Spronk3.   

Abstract

Dabigatran, a direct thrombin inhibitor, is increasingly used clinically as one of the new oral anticoagulants. This review summarizes the assays available to measure its activity and includes the relative sensitivity of the different assays for this agent. In addition to plasma-based clotting tests, assays commonly used in surgical/emergency settings, such as activated clotting time and thromboelastometry/thromboelastography, are reviewed. In addition, the thrombin generation assay is discussed as an important method to determine the potential risk of thrombosis or bleeding and its relevance to the measurement of direct thrombin inhibitors.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anticoagulation; Dabigatran; Measurement; Thrombin generation; Thromboelastometry

Mesh:

Substances:

Year:  2014        PMID: 25168938     DOI: 10.1016/j.cll.2014.06.008

Source DB:  PubMed          Journal:  Clin Lab Med        ISSN: 0272-2712            Impact factor:   1.935


  10 in total

1.  [Monitoring of NOAC].

Authors:  R B Zotz; L Weißbach
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-01-12       Impact factor: 0.840

Review 2.  Dabigatran etexilate: a review of its use in the treatment of acute venous thromboembolism and prevention of venous thromboembolism recurrence.

Authors:  Sarah L Greig; Kate McKeage
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

Review 3.  Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.

Authors:  Christina L Fanola
Journal:  Vasc Health Risk Manag       Date:  2015-05-27

4.  The use of frozen plasma samples in thromboelastometry.

Authors:  Christian Schoergenhofer; Nina Buchtele; Michael Schwameis; Johann Bartko; Bernd Jilma; Petra Jilma-Stohlawetz
Journal:  Clin Exp Med       Date:  2017-02-16       Impact factor: 3.984

5.  Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report.

Authors:  António Tralhão; Carlos Aguiar; Jorge Ferreira; Maria José Rebocho; Emília Santos; Dinis Martins; José Pedro Neves
Journal:  Thromb J       Date:  2017-09-05

6.  Volume replacement strategies do not impair the binding of dabigatran to idarucizumab: Porcine model of hemodilution.

Authors:  Oliver Grottke; Joanne van Ryn; Christian Zentai; Guanfa Gan; Markus Honickel; Rolf Rossaint; Hugo Ten Cate; Henri M H Spronk
Journal:  PLoS One       Date:  2019-01-07       Impact factor: 3.240

Review 7.  Perioperative management of patients receiving non-vitamin K antagonist oral anticoagulants: up-to-date recommendations.

Authors:  Kwang-Sub Kim; Jong Wook Song; Sarah Soh; Young-Lan Kwak; Jae-Kwang Shim
Journal:  Anesth Pain Med (Seoul)       Date:  2020-04-29

8.  The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency.

Authors:  Irina V Gribkova; Elena N Lipets; Irina G Rekhtina; Alex I Bernakevich; Dorzho B Ayusheev; Ruzanna A Ovsepyan; Fazoil I Ataullakhanov; Elena I Sinauridze
Journal:  Sci Rep       Date:  2016-07-05       Impact factor: 4.379

Review 9.  Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation.

Authors:  Oliver Grottke; James Aisenberg; Richard Bernstein; Patrick Goldstein; Menno V Huisman; Dara G Jamieson; Jerrold H Levy; Charles V Pollack; Alex C Spyropoulos; Thorsten Steiner; Gregory J Del Zoppo; John Eikelboom
Journal:  Crit Care       Date:  2016-04-28       Impact factor: 9.097

10.  Comparison of antithrombin-dependent and direct inhibitors of factor Xa or thrombin on the kinetics and qualitative characteristics of blood clots.

Authors:  Stella Salta; Loula Papageorgiou; Annette K Larsen; Patrick Van Dreden; Claire Soulier; Dennis V Cokkinos; Ismail Elalamy; Grigoris T Gerotziafas
Journal:  Res Pract Thromb Haemost       Date:  2018-07-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.